Variant Identification in BARD1, PRDM9, RCC1, and RECQL in Patients with Ovarian Cancer by Targeted Next-generation Sequencing of DNA Pools.

Malwina SuszynskaMagdalena Ratajska Paulina Galka-MarciniakAleksandra RyszkowskaDariusz WydraJaroslaw DebniakAnna Jasiak Bartosz WasagCezary CybulskiKozłowski Piotr

Published in: Cancer prevention research (Philadelphia, Pa.) (2022)

BARD1, PRDM9, RCC1, and RECQL are not high/moderate-risk ovarian cancer susceptibility genes. Pooled sequencing is a reliable and cost-effective method to detect rare variants in candidate genes.

Keyphrases

circulating tumor
copy number
renal cell carcinoma
bioinformatics analysis
genome wide
cell free
single cell
high intensity
single molecule
circulating tumor cells
randomized controlled trial
clinical trial
gene expression
drug delivery